Publications

2009

Elmasri H, Karaaslan C, Teper Y, Ghelfi E, Weng M, Ince TA, et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J. 2009;23(11):3865-73.
Chen C-, Tyler J. Selective sensitization of cancer cells to DNA damage by a HAT inhibitor. Cell Cycle. 2009;8(18):2867.
Martinez JL, Fajardo A, Garmendia L, Hernandez A, Linares JF, Martínez-Solano L, et al. A global view of antibiotic resistance. FEMS Microbiol Rev. 2009;33(1):44-65.
Galvez AS, Duran A, Linares JF, Pathrose P, Castilla EA, Abu-Baker S, et al. Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo. Mol Cell Biol. 2009;29(1):104-15.
Solomon JP, Yonemoto IT, Murray AN, Price JL, Powers ET, Balch WE, et al. The 8 and 5 kDa fragments of plasma gelsolin form amyloid fibrils by a nucleated polymerization mechanism, while the 68 kDa fragment is not amyloidogenic. Biochemistry. 2009;48(48):11370-80.
Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009;15(9):3023-8.
Ma Q, Cavallin LE, Yan B, Zhu S, Duran EM, Wang H, et al. Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma. Proc Natl Acad Sci U S A. 2009;106(21):8683-8.
Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A, et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood. 2009;113(15):3397-405.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700